Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia

This study has been completed.
National Cancer Institute (NCI)
Astex Pharmaceuticals
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center Identifier:
First received: October 5, 2007
Last updated: January 7, 2016
Last verified: January 2016
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: January 2016
  Primary Completion Date: January 2016 (Final data collection date for primary outcome measure)